Merck Reports Results from the P-III (KEYNOTE-B21) Study of Keytruda Plus Chemotherapy for Endometrial Cancer
Shots:
- The P-III (KEYNOTE-B21) study assesses Keytruda + CT with/without radiotherapy vs PBO to treat newly-diagnosed patients (n=1,095) with high-risk endometrial cancer post-surgery with curative intent
- The study did not meet the 1EP of DFS while OS was not tested due to non-attainment of DFS; safety profile was favorable without any new signals. Full assessment continues with results anticipated at a scientific community
- Merck’s endometrial carcinoma trials include NRG-GY018 study of Keytruda + SoC CT followed by Keytruda alone, with the US FDA’s priority review (PDUFA date: Jun 21, 2024); KEYNOTE-C93 study of Keytruda vs CT & MK-2870-005 study of sacituzumab tirumotecan vs physicians' choice treatment in patients previously treated with Pt-based CT & immunotx.
Ref: Merck | Image: Merck
Related News:- Merck Reports the P-III (KEYNOTE-811) Study Data of Keytruda Plus Trastuzumab and Chemotherapy for G/GEJ Adenocarcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
